Research Paper Volume 13, Issue 12 pp 16696—16712

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma

Relationship between TNFRSF14 expression and prognosis of EC patients. (A) TNFRSF14 expression in pan-carcinoma tissues. (B) Relationship between TNFRSF14 expression and clinical stages of endometrial cancer. (C) Relationship between TNFRSF14 expression and TP53 mutations in EC. (D) Relationship between TNFRSF14 expression and tissue subtypes of EC. (E) TNFRSF14 expression in endometrial cancer tissues. (F) TNFRSF14 expression in normal endometrial tissues. (G) Kaplan-Meier survival analysis shows the relationship between TNFRSF14 expression and prognosis of EC patients using the KM Plotter database.

Figure 10. Relationship between TNFRSF14 expression and prognosis of EC patients. (A) TNFRSF14 expression in pan-carcinoma tissues. (B) Relationship between TNFRSF14 expression and clinical stages of endometrial cancer. (C) Relationship between TNFRSF14 expression and TP53 mutations in EC. (D) Relationship between TNFRSF14 expression and tissue subtypes of EC. (E) TNFRSF14 expression in endometrial cancer tissues. (F) TNFRSF14 expression in normal endometrial tissues. (G) Kaplan-Meier survival analysis shows the relationship between TNFRSF14 expression and prognosis of EC patients using the KM Plotter database.